Correlation Between Serum TK1 and Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy

Launched by YUNNAN CANCER HOSPITAL · Jul 13, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether a specific blood marker, called serum TK1, can help predict how well breast cancer patients respond to a type of treatment known as neoadjuvant chemotherapy. Neoadjuvant chemotherapy is given before surgery to shrink the tumor. Researchers are looking at the levels of TK1 in the blood at different points during treatment to see if changes in its levels can indicate whether the cancer is responding well.

To participate in this trial, women aged 65 to 74 who have been diagnosed with breast cancer and have complete medical records may be eligible. They need to have received neoadjuvant chemotherapy and have had a surgery afterward, with all necessary tests completed. Participants will have their blood levels monitored throughout the treatment to help researchers build a model that predicts treatment success. This study is currently recruiting, and it's important for potential participants to know they cannot have advanced stage cancer or other types of cancer to qualify.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • ① The patient was diagnosed with breast cancer by biopsy, and there were complete pathological data. ② Complete the course of neoadjuvant chemotherapy; ③ After the end of neoadjuvant therapy, the operation was performed and the postoperative pathology was obtained; MRI and serum TK1 data were complete (baseline, after 2 cycles of chemotherapy, 4 cycles of chemotherapy, and 6 cycles of chemotherapy).
• Exclusion Criteria:
• • ① Distant metastasis at first diagnosis (stage IV); ② With other primary malignant tumors.